The backbone of medical therapies used to treat metabolic syndrome utilizes analogs of the main incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Here, GLP1R is linked to metabolic syndrome.